- €116.31m
- €386.34m
- €786.44m
Guerbet Q1 revenue up 2.6% at CER on increased volumes in EMEA and Asia
Medical imaging firm Guerbet's 2025 revenue falls on lower sales activity in France
Brief: Guerbet Says FDA Approves Labeling Update For Guerbet's Elucirem Injection
France's Guerbet misses 2025 revenue estimates
Brief: Guerbet Appoints Karim Boussebaa CEO
Brief: European Commission approves Guerbet's half-dose GBCA, Elucirem for newborns and children
Guerbet tracks for worst day ever after Raleigh site-induced guidance cut
Brief: Guerbet Cuts Full-Year 2025 Financial Targets
Brief: Guerbet Cuts FY 2025 Guidance
Brief: Guerbet's AGM Votes To Reduce Directors' Terms Of Office To 4 Years
Brief: Guerbet Q1 2025 Revenue EUR 180.1 Mln
Brief: Guerbet FY Revenue Up At EUR 841.1 Mln
Brief: Guerbet Sees FY Revenue Growth Of Over 9% LfL
Brief: Guerbet Confirms Its Financial Targets For 2024
Brief: Guerbet Names Hugues Lecat As New Chairman Of Board Of Directors
Brief: Guerbet Q1 Revenue Up At Eur 194.3 Mln
Brief: Guerbet FY Net Income Turns To Profit Of Eur 22.2 Million
Brief: Guerbet FY Revenue Up At EUR 785.7 Mln
Brief: Guerbet Announces Marketing Authorisation Approval Of Elucirem™ (Gadopiclenol) In The European Union